Assessing SARS-CoV-2 Circulation, Variants of Concern, Non-Pharmaceutical Interventions and Vaccine Rollout in the EU/EEA, 16th Update [open pdf - 0B]
From the Summary: "Since its emergence in March 2021, the B.1.617.2 (Delta) variant of concern (VOC) has rapidly become predominant across the European Union/European Economic Area (EU/EEA). More than 99% of newly reported cases are attributed to this variant. The Delta variant has demonstrated a significant transmission advantage relative to previously circulating SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] strains. However, full vaccination remains protective against severe outcomes such as hospitalisation, admission to intensive care and death. Currently available vaccines have played a crucial role in limiting viral circulation and in particular, limiting the impact of infections by the Delta variant. Despite the fact that over 565 million vaccine doses have been administered in the EU/EEA so far, only 61.1% (range: 18.4-79.4%) of the total population in the EU/EEA have been fully vaccinated to date. The total population includes children and adolescents for whom the vaccine is not available or who may not be included in national target groups yet. There is considerable inter-country and sub-national variation in vaccine uptake, resulting in large proportions of the EU/EEA population remaining susceptible to SARS-CoV-2 infection. Modelling scenarios that consider vaccination coverage, vaccine effectiveness, natural immunity and population contact rates--in the context of continued Delta circulation--indicate that the potential burden of disease risk in the EU/EEA from the Delta variant is high between now to the end of November, unless vaccination coverage can be increased rapidly in the total population in the next few weeks."
2021 European Centre for Disease Prevention and Control, Stockholm
European Centre for Disease Prevention and Control: https://www.ecdc.europa.eu/